

2025 Annual Report



MISSION STATEMENT

Putting people with lupus at the center of all we do, the Lupus Research Alliance drives the discovery and development of next-generation lupus diagnostics and curative treatments through innovative research and collaborations.

TOGETHER, WE ARE MOVING TOWARD A CURE

2025 was an extraordinary year for the lupus community and the Lupus Research Alliance. Together, we are advancing innovative research and accelerating progress toward our vision: a world free of lupus. Fueled by your support, we remain steadfast in our commitment to drive discovery across the full continuum of lupus research – from understanding disease mechanisms to delivering new therapies for the millions living with lupus around the world.

A YEAR OF BREAKTHROUGHS AND BOLD ACTION

The Lupus Research Alliance invested nearly \$13 million in innovative lupus research in 2025, bringing our total investment since 1999 to more than \$284 million and supporting over 675 individual research awards. This funding from the Lupus Research Alliance continued to drive high-impact research and collaboration, bringing us closer to better diagnostics, more effective treatments, and ultimately a cure.

IMPACT MADE POSSIBLE BY YOU

This year is proof that the promise of progress is possible – and that together, we are stronger than lupus. In 2025, we:

- Invested in groundbreaking science from more than 25 researchers who are working hard to unlock personalized diagnostics and treatments for those with this disease. The Lupus Research Alliance's signature grant programs are driving discovery – exploring game-changing engineered cell therapies, uncovering the underlying causes of lupus, fostering promising talent, generating key learnings for the broader autoimmune space, and more.
- Achieved critical clinical trial progress through our clinical affiliate, Lupus Therapeutics, which is involved in more than 25% of active lupus clinical trials, helping advance novel therapies through broad clinical expertise, strong research partnerships, and community engagement.
- Awarded the first recipient of the IDEAL initiative – led by Lupus Therapeutics – to a first-of-its-kind pilot study on diet in lupus led by Monica Guma, MD, PhD, and colleagues at the University of California-San Diego.
- Celebrated a major clinical milestone with a new U.S. Food & Drug Administration (FDA)-approved therapy for lupus nephritis, after funding more than 80 foundational research projects that are paving the way for innovative treatment advances.
- Made major strides through the Lupus Accelerating Breakthroughs Consortium, the only public-private partnership with the FDA focused on lupus, by standardizing measurement tools for cutaneous lupus, creating collective considerations for advancing engineered cell therapies, and showcasing to the industry the importance of patient-reported outcomes and how to integrate them in clinical research.
- Launched new, expansive data sets to further scientific breakthroughs via the Lupus Nexus, our unique lupus registry, biorepository, and information exchange platform that drives in-depth research to further the understanding and treatment of lupus.
- Strengthened collaborations with partners, including Breakthrough T1D, the National Multiple Sclerosis Society, and the Rheumatology Research Foundation, to explore shared disease pathways and to support next-generation talent fueling lupus breakthroughs.
- Led critical advocacy efforts in Washington, D.C. to restore millions of dollars in funding for the Department of Defense Lupus Research Program.
- Engaged thousands of lupus community members at signature Lupus Research Alliance *Walk with Us to Cure Lupus* events, the 2025 Breaking Through Gala, and others.

FROM YOUR VOICE COMES PROGRESS

Our community is at the heart of everything we do. We are deeply grateful to every individual who has shared their story, participated in clinical research, walked beside us, raised awareness, and helped propel lupus research forward. Your voices, actions, and advocacy make progress possible – and bring us closer to a cure.

“The Lupus Research Alliance is doing critical work to better understand this disease and develop new treatments. Being part of that effort gives me hope for the future.”

Faith Majors
Actress, writer &
speaker living
with lupus



LUPUS RESEARCH ALLIANCE REMAINS ONE OF THE MOST TRUSTED HEALTH ORGANIZATIONS

The Lupus Research Alliance is proud to be recognized as one of the best charities worldwide. The Lupus Research Alliance earned four out of four stars by Charity Navigator, the Gold Seal of Transparency from Guidestar, recognition as a BBB Wise Giving Accredited Charity, and a “Top Rated” status with an “A” ranking from nonprofit evaluator CharityWatch.


The following is an overview of the Lupus Research Alliance’s income and expenditures for the fiscal year ending December 31, 2025.*

Revenue & Other Support:	
Contributions	\$ 12,046,822
Other Support	\$ 14,935,025
Total Revenue & Other Support:	\$26,981,847
Program Expenditures:	
Research	\$ 15,426,770
Scientific programs	\$ 17,084,288
Public policy	\$ 645,427
Total Program Expenditures:	\$33,156,485
Administration Expenditures:	\$ 3,479,359**
Fundraising Expenditures:	\$ 4,884,285**
End-of-Year Net Asset Balance:	\$48,678,127

Because the Lupus Research Alliance Board of Directors funds our administrative and fundraising costs, 100% of your contribution to the Lupus Research Alliance go directly to support lupus research programs.

* The FY2025 deficit reflects planned investments in research supported by previously recognized multi-year funding and accumulated reserves.

** The Lupus Research Alliance’s Supporting Services are covered by donations from its Board of Directors.



OUR CORPORATE & INSTITUTIONAL PARTNERS

The Lupus Research Alliance extends its gratitude to the corporate sponsors who help make this work possible. With donations of \$25,000 or more, that includes: AbbVie; AbelZeta Pharma; Adicet Bio; Amgen; AstraZeneca; Autolus; Bank of America; Biogen; Bloomberg L.P.; Bristol-Myers Squibb; Cabaletta Bio; Capital Group Company Charitable Foundation; Caribou Biosciences; CRISPR Therapeutics; Cullinan Therapeutics; Dartmouth Hitchcock Medical Center; Eastdil Secured, LLC; Eli Lilly; EMD Serono; Fate Therapeutics; Genentech; General Atlantic Foundation; Gilead Sciences; GlaxoSmithKline; Hinge Bio; Hospital for Special Surgery; iCell Gene Therapeutics Inc.; Immunovant Inc.; Johnson & Johnson; Jones Lang LaSalle; Kyowa Kirin; Lupus and Allied Diseases Association; Merck (USA); National Football League; National Land Tenure Company, LLC; New York Jets Foundation; NFL Foundation; Nkarta, Inc.; Northwell Health; Novartis; Paul, Weiss, Rifkind, Wharton & Garrison LLP; Pfizer; Publicis; Regeneron Pharmaceuticals, Inc.; RWJ Barnabas Health; Sanofi; Secunda Family Foundation; Tunnel to Towers Foundation; UCB; Verizon; Wells Fargo; and, Zenas BioPharma.

Board of Directors

We extend our sincere gratitude and appreciation to our Board of Directors, who fund all our administration and fundraising expenses. Their ongoing generosity allows us to commit 100% of all other donations to support lupus research programs.

- Ira Akselrad, Chair
- Anna Roffwarg Fisch, Secretary
- Joseph Mauriello, Treasurer
- James Andrew
- Bishop Rudy V. Carlton
- Andrew C. Chan, MD, PhD
- William “Willie” Colon
- Jennifer A Dakin
- Jennie L. DeScherer
- Katey Driscoll
- Joe Germanotta
- Xavier V. Goss, CFA
- David M. Kies
- Veronica Vargas Lupo
- Nadeem Meghji
- Nidhi Patel
- Lisa Hertz Robinson
- Robert Seder, MD
- Daniel J. Wallace, MD, FACP, MACR
- Julius Williams
- William J. Wolfe
- Spencer Zwick

Officers

- Albert T. Roy, President & CEO
- Nicole Capossela, Chief Advancement Officer
- Debra Rose, Chief Financial Officer
- Teodora Staeva, PhD, Chief Scientific Officer
- Nishant Rastogi, Managing Director, Lupus Ventures LLC
- Luke Easley, Senior VP, HR and Administration
- Penny Mitchell, VP, Marketing and Communications
- Andrea J. O’Neill, VP, Development

Scientific Advisory Board

- Andrew C. Chan, MD, PhD, Chair
- Laurent Arnaud, MD, PhD
- Roberto Caricchio, MD
- Kate Fitzgerald, PhD
- Nancy Mize Gonzalez
- Arezou Khosroshahi, MD
- Andrea Knight, MD
- Jason Williams
- Julie Zikherman, MD

